Novel estrogen-conjugated pyridine-containing Gd(III) and Eu(III) contrast agents (EPTA-Gd/Eu) were designed and effectively synthesized. Convenient to administration and MRI experiments, both EPTA-Gd and EPTA-Eu are soluble in water. The EPTA-Gd selectively binds with a micromolar affinity to the estrogen receptor and induces proliferation of human breast cancer cells. The EPTA-Gd is not lethal and does not cause any adverse effects when administrated intravenously. It enhances T1 and T2 nuclear relaxation rates of water and serves as a selective contrast agent for localizing the estrogen receptor by MRI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/bc700230m | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CYP19 and ESR2 polymorphisms as potential culprits in cryptorchidism.
J Pediatr Urol
December 2024
Muğla Sıtkı Koçman University, Faculty of Medicine, Department of Pediatric Surgery, Muğla, Turkey.
Introduction: Cryptorchidism impairs sperm development and increases the risk of infertility and testicular cancer. Estrogen signalling is critical for proper descent of the testicles, and hormonal imbalances play a role in cryptorchidism. CYP19, also known as aromatase, encodes an enzyme that converts testosterone, a male sex hormone, into estradiol, the main form of estrogen.
View Article and Find Full Text PDFNeratinib enhances the efficacy of CDK4/6 inhibitor plus endocrine therapy in HR/HER2-low breast cancer cell line ZR-75-1 via hsa-miR-23a-5p.
Sci Rep
December 2024
Chinese Medicine Guangdong Laboratory, Hengqin, 519031, Guangdong, China.
HR/HER2-low breast cancer is a significant subgroup of conventional HR/HER2-negative breast cancer, and combination of CDK4/6 inhibitor and endocrine therapy is the standard first-line and second-line treatments for advanced HR/HER2-low breast cancer. Nevertheless, it remains uncertain whether HER2 signaling affects the effectiveness of CDK4/6 inhibitor administered in combination with endocrine therapy for HR/HER2-low breast cancer and suitable intervention measures. This study revealed poor efficacy for CDK4/6 inhibitor combined with endocrine therapy for HR/HER2-low breast cancer in vitro and in vivo models.
View Article and Find Full Text PDFG Protein-coupled Estrogen Receptor 1 (GPER1) Regulates Expression of /PAI-1 and Inhibits Tumorigenic Potential of Cervical Squamous Cell Carcinoma Cells .
Cancer Genomics Proteomics
December 2024
University Medical Center Göttingen, Department of Gynecology and Obstetrics, Göttingen, Germany
Background/aim: G protein-coupled estrogen receptor 1 (GPER1) appears to play a tumor-suppressive role in cervical squamous cell carcinoma (CSCC)GPER1 suppression leads to significantly increased expression of serpin family E member 1 (SERPINE1)/protein plasminogen activator inhibitor type 1 (PAI-1). The question arises, what role does SERPINE1/PAI-1 play in GPER1-dependent tumorigenic potential of CSCC.
Materials And Methods: SiHa and C33A CSCC cells were treated with GPER1 agonist G1 or antagonist G36.
Hormone therapy enhances anti-PD1 efficacy in premenopausal estrogen receptor-positive and HER2-negative advanced breast cancer.
Cell Rep Med
December 2024
Department of Medical Oncology, National Taiwan University Cancer Center, Taipei City 106, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City 100, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei City 100, Taiwan. Electronic address:
The efficacy of immunotherapy for estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC) has not been proven. We conduct a phase 1b/2 trial to assess the efficacy of combining pembrolizumab (anti-PD1 antibody), exemestane (nonsteroidal aromatase inhibitor), and leuprolide (gonadotropin-releasing hormone agonist) for 15 patients with premenopausal ER+/HER2- MBC who had failed one to two lines of hormone therapy (HT) without chemotherapy. The primary endpoint of progression-free survival rate at 8 months (i.
View Article and Find Full Text PDFRole of centchroman in regression of fibroadenoma: A 2-arm randomized control trial.
Clinics (Sao Paulo)
December 2024
Department of General Surgery, Dr. RMLIMS, Lucknow, Uttar Pradesh, India.
Background: Fibroadenomas are common benign breast lumps that can cause anxiety due to malignancy concerns, and Centchroman, a selective estrogen receptor modulator, has shown promise in reducing their size. This study aimed to evaluate the efficacy of Centchroman in reducing fibroadenoma size, mastalgia, anxiety, and depression in affected patients.
Methodology: A parallel-arm randomized controlled trial was conducted at a tertiary care Breast Clinic with 104 patients aged 18‒45 years having fibroadenomas ≤ 3 cm.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!